Get the Stockscreener App
11.18
2.70%
-0.31
Atrium Therapeutics Inc stock is traded at $11.18, with a volume of 119.41K.
It is down -2.70% in the last 24 hours and down -18.10% over the past month.
Atrium Therapeutics Inc is a biopharmaceutical firm focused on developing RNA-based therapeutics for cardiac conditions, including cardiomyopathies. Its platform technology is designed to enable targeted delivery of RNA therapeutics to heart tissue by combining ligand-based targeting approaches with oligonucleotide-based therapies. The company's development pipeline includes programs targeting genetically associated forms of cardiomyopathy, specifically involving the PRKAG2 and PLN genes.
See More
Previous Close:
$11.49
Open:
$11.46
24h Volume:
119.41K
Relative Volume:
0.59
Market Cap:
$191.24M
Revenue:
$10.73M
Net Income/Loss:
$-455.74M
P/E Ratio:
-2.9554
EPS:
-3.7829
Net Cash Flow:
$-502.70M
1W Performance:
-8.13%
1M Performance:
-18.10%
6M Performance:
-84.59%
1Y Performance:
-68.90%
1-Day Range:
$11.13
$11.46
1-Week Range:
$11.13
$12.14
52-Week Range:
$11.13
$73.06
Atrium Therapeutics Inc Stock (RNA) Company Profile
Name
Atrium Therapeutics Inc
Sector
Industry
Phone
858-401-7900
Address
3020 CALLAN ROAD, SAN DIEGO, CA
Compare RNA vs VRTX, REGN, ARGX, RVMD, ALNY
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RNA
Atrium Therapeutics Inc
|
11.18 | 197.91M | 10.73M | -455.74M | -502.70M | -3.7829 |
VRTX
Vertex Pharmaceuticals Inc
|
483.33 | 121.57B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
695.42 | 69.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
882.56 | 55.61B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
180.92 | 39.98B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
286.62 | 37.17B | 4.29B | 577.22M | 641.34M | 4.2086 |
Atrium Therapeutics Inc Stock (RNA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-11-26 | Initiated | Wells Fargo | Overweight |
| Sep-17-25 | Initiated | Roth Capital | Buy |
| Jul-10-25 | Resumed | Goldman | Buy |
| Jun-24-25 | Initiated | Bernstein | Outperform |
| Jun-17-25 | Initiated | Wolfe Research | Outperform |
| Jun-11-25 | Initiated | Raymond James | Strong Buy |
| Mar-13-25 | Initiated | Citigroup | Buy |
| Mar-12-25 | Initiated | BMO Capital Markets | Outperform |
| Mar-07-25 | Initiated | Scotiabank | Sector Outperform |
| Dec-20-24 | Initiated | H.C. Wainwright | Buy |
| Nov-26-24 | Initiated | RBC Capital Mkts | Outperform |
| Sep-24-24 | Initiated | Goldman | Buy |
| Aug-28-24 | Initiated | Barclays | Overweight |
| May-03-24 | Initiated | BofA Securities | Buy |
| Mar-14-24 | Initiated | Cantor Fitzgerald | Overweight |
| May-22-23 | Upgrade | Evercore ISI | In-line → Outperform |
| Mar-31-23 | Downgrade | Evercore ISI | Outperform → In-line |
| Jul-20-22 | Initiated | Chardan Capital Markets | Buy |
| Jul-12-22 | Initiated | Raymond James | Strong Buy |
| Sep-07-21 | Initiated | Evercore ISI | Outperform |
| Jun-17-21 | Initiated | Needham | Buy |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Jul-07-20 | Initiated | Cowen | Outperform |
| Jul-07-20 | Initiated | Credit Suisse | Outperform |
| Jul-07-20 | Initiated | SVB Leerink | Outperform |
| Jul-07-20 | Initiated | Wells Fargo | Overweight |
View All
Atrium Therapeutics Inc Stock (RNA) Latest News
BlackRock (RNA holder) discloses 6.6% Atrium Therapeutics stake in amended ownership filing - Stock Titan
Atrium Therapeutics, Inc. Revenue Breakdown – NASDAQ:RNA - TradingView
Atrium Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - PR Newswire
Atrium Therapeutics’ new hire receives options and 3,500 stock units - Stock Titan
Atrium Therapeutics (RNA): Flat Trading as Stock Hovers Near Key Support LevelsMonthly Profile - dars.gov.et
Wells Fargo Remains a Buy on Atrium Therapeutics, Inc. (RNA) - The Globe and Mail
Atrium Therapeutics Inc. (RNA) Q1 2026 Earnings: Narrower-Than-Expected Loss as Pre-Commercial Spend Weighs on ResultsFree Cash Flow Trends - dars.gov.et
Atrium Therapeutics Inc. (RNA) Q1 2026 Earnings: Narrower-Than-Expected Loss Provides a Modest SurpriseLow Estimate Range - dars.gov.et
Wells Fargo Maintains Atrium Therapeutics(RNA.US) With Buy Rating, Maintains Target Price $25 - Moomoo
Atrium’s ATR-1072 gains IND clearance for PRKAG2 syndrome - BioWorld News
Atrium Therapeutics Receives FDA Clearance for ATR 1072, Launches First Clinical Trial Targeting PRKAG2 Syndrome - Minichart
FDA Clears Atrium Therapeutics' IND Application for Cardiomyopathy Drug - dicardiology.com
Atrium Therapeutics (Nasdaq: RNA) prepares Corventis PRKAG2 trial launch - Stock Titan
Atrium Therapeutics Secures FDA Clearance for ATR 1072 Trial - grafa.com
Atrium gets FDA clearance for PRKAG2 syndrome trial - Investing.com UK
Atrium gets FDA clearance for PRKAG2 syndrome trial By Investing.com - Investing.com Nigeria
FDA clears Atrium Therapeutics' IND for ATR 107... - Pluang
Atrium Therapeutics Announces FDA Clearance of Investigational New Drug Application for ATR 1072 for Treatment of PRKAG2 Syndrome - PR Newswire
Atrium's First PRKAG2 Trial to Evaluate Treatment for Disease Cause - Stock Titan
Atrium Therapeutics (RNA) Slips 3.5% as Biotech Headwinds IntensifySuperTrend - dars.gov.et
Enterprise value to revenue forward of Atrium Therapeutics, Inc. – NASDAQ:RNA - TradingView
Price to earnings forward of Atrium Therapeutics, Inc. – NASDAQ:RNA - TradingView
Enterprise value to EBIT forward of Atrium Therapeutics, Inc. – NASDAQ:RNA - TradingView
Price to sales forward of Atrium Therapeutics, Inc. – NASDAQ:RNA - TradingView
Atrium Therapeutics Inc. (RNA) Stock Price | Live Quotes & Charts | NASDAQ - timothysykes.com
Atrium Therapeutics (RNA) Slips 3% as Shares Test Key Support at $12.31Delta Hedging - dars.gov.et
RNA News | ATRIUM THERAPEUTICS INC (NASDAQ:RNA) - ChartMill
Atrium Therapeutics, Inc.(NasdaqGS:RNA) added to Russell Microcap Value Benchmark Index - marketscreener.com
Atrium Therapeutics, Inc. (RNA) Stock Analysis: A Biotech Company Poised for Nearly 90% Upside - DirectorsTalk Interviews
Atrium Therapeutics, Inc.(NasdaqGS: RNA) added to Russell 3000E Growth Benchmark - marketscreener.com
Atrium Therapeutics Inc. (RNA) Q1 2026 Earnings: Narrowed Loss Per Share Beats Expectations Amid Clinical ProgressFiscal Year Earnings - dars.gov.et
Atrium Therapeutics, Inc.(NasdaqGS: RNA) added to Russell Microcap Index - marketscreener.com
Atrium Therapeutics, Inc.(NasdaqGS: RNA) added to Russell 3000E Index - marketscreener.com
RNA Forecast — Price Target — Prediction for 2027 - TradingView
Atrium Therapeutics, Inc. Actuals & Estimates (NASDAQ:RNA) - TradingView
RNA Technical Analysis & Stock Price Forecast - Intellectia AI
Atrium Therapeutics Faces Modest Pullback as Support Levels Under ScrutinyCash Secured Put - dars.gov.et
Arbiter Partners Capital Management LLC's Atrium Therapeutics Inc(RNA) Holding History - GuruFocus
Cantor Fitzgerald Initiates Atrium Therapeutics(RNA.US) With Buy Rating, Announces Target Price $25 - Moomoo
Atrium Therapeutics Inc. (RNA) Q1 2026 Earnings: EPS Beat Amid Pre-Revenue Stage; Stock Inches HigherOperating Margin Analysis - Město Břeclav
Atrium Therapeutics, Inc. (RNA) Stock Analysis: Unveiling a 111.86% Potential Upside in the Biotech Arena - DirectorsTalk Interviews
Atrium Therapeutics Inc. (RNA) Q1 2026 Earnings: Narrower Loss Beats Estimates Amid Pipeline Progress - newsline.com
Atrium Therapeutics Inc. (RNA) Q1 2026 Earnings: EPS Beats Estimates Despite Pre-Revenue Status; Stock Drops on Cash Burn ConcernsEPS Miss Report - newsline.com
Atrium Therapeutics Inc. (RNA) Q1 2026 Earnings: EPS Beat Amidst Clinical Progress and Cost DisciplineMid-Term Outlook - dars.gov.et
Atrium Therapeutics, Inc. (RNA) - DirectorsTalk Interviews
Atrium Therapeutics Inc. (RNA) Q1 2026 Earnings: Narrower-Than-Expected Loss Highlights Operational Discipline - dars.gov.et
RNAAtrium Therapeutics Inc Forecast, Target Price - Finviz
RNA Price Today: Atrium Therapeutics, Inc. Stock Price, Quote & Chart | MEXC - MEXC
Atrium Therapeutics Inc. (RNA) Q1 2026 Earnings: Narrower Loss Drives EPS Beat, but Stock SlipsGAAP Earnings Report - dars.gov.et
Here's Why We're Not Too Worried About Atrium Therapeutics' (NASDAQ:RNA) Cash Burn Situation - Yahoo Finance
Atrium Therapeutics Inc. (RNA) Holds Steady Near Resistance as Momentum BuildsCash Flow Strong Stocks - newsline.com
Atrium Therapeutics Inc Stock (RNA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Atrium Therapeutics Inc Stock (RNA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Boyce Sarah | President and CEO |
Jan 21 '26 |
Sale |
72.45 |
14,387 |
1,042,338 |
269,007 |
| Flanagan W. Michael | Chief Scientific Officer |
Jan 21 '26 |
Sale |
72.45 |
6,534 |
473,388 |
85,093 |
| MacLean Michael F | Chief Financial Officer |
Jan 21 '26 |
Sale |
72.45 |
4,542 |
329,068 |
59,290 |
| LEVIN ARTHUR A | Director |
Jan 21 '26 |
Sale |
72.45 |
1,758 |
127,367 |
16,562 |
| McCarthy Teresa | Chief Human Resources Officer |
Jan 21 '26 |
Sale |
72.45 |
2,929 |
212,206 |
113,938 |
| Boyce Sarah | President and CEO |
Jan 07 '26 |
Sale |
72.23 |
8,576 |
619,444 |
283,394 |
| Calderaro Charles III | Chief Technical Officer |
Jan 07 '26 |
Sale |
72.23 |
3,727 |
269,201 |
49,797 |
| McCarthy Teresa | Chief Human Resources Officer |
Jan 07 '26 |
Sale |
72.23 |
1,965 |
141,932 |
116,867 |
| Moriarty John B | Chief Legal Officer |
Jan 07 '26 |
Sale |
72.23 |
2,374 |
171,474 |
74,557 |
| MacLean Michael F | Chief Financial Officer |
Jan 07 '26 |
Sale |
72.23 |
1,974 |
142,582 |
63,832 |
0.54%
2.87%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):